Heidi Henson Biography and Net Worth

Ms. Henson was appointed to the Lisata Board in September 2022 and serves as the Chairman of the Audit Committee. Ms. Henson possesses two decades of financial operations experience with both public and private companies. In addition, Ms. Henson currently serves on the board of directors of PepGen and Perspective Therapeutics.

Ms. Henson previously served as Chief Financial Officer at Pardes Biosciences where she was instrumental in completing their tender offer transaction, as well as their de-SPAC transaction.

Prior to Pardes, she served as the Chief Financial Officer for Imbria Pharmaceuticals, Kura Oncology, Wellspring Biosciences, and their parent company, Araxes Pharma.

Ms. Henson holds a BS in Accounting from the University of San Diego and is a Certified Public Accountant (currently inactive) in California.

What is Heidi Henson's net worth?: The estimated net worth of Heidi Henson is at least $62.08 thousand as of December 4th, 2024. Ms. Henson owns 25,975 shares of Perspective Therapeutics stock worth more than $62,080 as of December 4th. This net worth evaluation does not reflect any other investments that Ms. Henson may own. Learn More about Heidi Henson's net worth.
How do I contact Heidi Henson?: The corporate mailing address for Ms. Henson and other Perspective Therapeutics executives is 2401 Elliott Avenue, Suite 320, Seattle, WA 98121, United States. Perspective Therapeutics can also be reached via phone at 206-676-0900 and via email at [email protected]. Learn More on Heidi Henson's contact information.
Has Heidi Henson been buying or selling shares of Perspective Therapeutics?: Heidi Henson has not been actively trading shares of Perspective Therapeutics in the last ninety days. Most recently, on Wednesday, December 4th, Heidi Henson bought 25,975 shares of Perspective Therapeutics stock. The stock was acquired at an average cost of $3.85 per share, with a total value of $100,003.75. Following the completion of the transaction, the director now directly owns 25,975 shares of the company's stock, valued at $100,003.75. Learn More on Heidi Henson's trading history.
Who are Perspective Therapeutics' active insiders?: Perspective Therapeutics' insider roster includes Juan Graham (CFO), Heidi Henson (Director), Jonathan Hunt (CFO), Markus Puhlmann (Chief Medical Officer), Johan Spoor (CEO), Robert Williamson, III (Director), and Lori Woods (Director). Learn More on Perspective Therapeutics' active insiders.
Are insiders buying or selling shares of Perspective Therapeutics?: In the last twelve months, Perspective Therapeutics insiders bought shares 8 times. They purchased a total of 170,169 shares worth more than $428,783.18. The most recent insider tranaction occured on November, 13th when CAO Jonathan Robert Hunt bought 11,000 shares worth more than $22,330.00. Insiders at Perspective Therapeutics own 3.7% of the company. Learn More about insider trades at Perspective Therapeutics.
Information on this page was last updated on 11/13/2025.

Heidi Henson Insider Trading History at Perspective Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/4/2024	Buy	25,975	$3.85	$100,003.75	25,975

Heidi Henson Buying and Selling Activity at Perspective Therapeutics

Perspective Therapeutics Company Overview

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Today's Range

Now: $2.39

$2.17

$2.41

50 Day Range

MA: $2.94

$2.05

$4.98

2 Week Range

Now: $2.39

$1.60

$5.39

Volume

1,930,567 shs

Average Volume

1,946,208 shs

Market Capitalization

$177.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22